Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Thoracic 1

Conditions

Breast Neoplasms 369Carcinoma, Non-Small-Cell Lung 315Neoplasms 289Prostatic Neoplasms 245Colorectal Neoplasms 214Multiple Myeloma 182Lung Neoplasms 170Neoplasm Metastasis 152Leukemia, Myeloid, Acute 137Pancreatic Neoplasms 130Squamous Cell Carcinoma of Head and Neck 127Ovarian Neoplasms 117Melanoma 98Carcinoma, Renal Cell 94Recurrence 87Stomach Neoplasms 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 80Carcinoma, Hepatocellular 80Lymphoma, Non-Hodgkin 79Head and Neck Neoplasms 79Lymphoma 78Glioblastoma 78Triple Negative Breast Neoplasms 76Lymphoma, Large B-Cell, Diffuse 75Urinary Bladder Neoplasms 69Endometrial Neoplasms 68Brain Neoplasms 68Leukemia, Lymphocytic, Chronic, B-Cell 65Uterine Cervical Neoplasms 62Lymphoma, Follicular 62

Interventions

Nivolumab 2tivozanib 1encorafenib 1durvalumab 1Thioctic Acid 1Oxaliplatin 1Multiparametric Magnetic Resonance Imaging 1Leucovorin 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Cisplatin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Disease Progression × 30 days × Clear all
NCT05712356 2026-05-26

BOLSTER

Lisata Therapeutics, Inc.

Phase 2 Terminated
66 enrolled 12 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
38 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 3 Completed
343 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

NCT07574684 2026-05-08

ALA /NSCLC

Ain Shams University

Phase 2 Not yet recruiting
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Disease Progression

NCT04692675 2026-05-06

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase NA Recruiting
508 enrolled
Genitourinary

Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡